European Industry Played Key Role In Mitigating COVID-19
Detailed Modelling And Industry Co-ordination Were Central To Managing Pandemic
In the first part of an exclusive two-part interview, James Burt – Accord’s executive vice-president for Europe, the Middle East and North Africa – talks to Generics Bulletin about the key actions taken by the generics industry to mitigate the coronavirus pandemic, and the changed landscape that the off-patent arena can expect to see in future.
You may also be interested in...
Planned reforms to the EU’s Schengen open border system that will allow for transport “green lanes” to be reactivated when necessary have been welcomed by off-patent industry association Medicines for Europe.
Ahead of an upcoming European Council meeting covering the EU’s industrial policy and ongoing response to the COVID-19 pandemic, Medicines for Europe has set out what it sees as key policy objectives to consider.
Weaknesses in the global pharmaceutical supply chain, exposed and exacerbated by the coronavirus pandemic, have led major markets to pursue localization policies aimed at bolstering domestic production capacity. But any significant transformation promises to take many years.